Global University Venturing

Third Rock Ventures has led a series A round for Abata Therapeutics, launched by the firm to commercialise research from Harvard, MIT, Johns Hopkins, NIH and UZH.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Gene therapy developer Corlieve, which utilises University of Bordeaux, Aix Marseille University, CNRS and Inserm research, is set to be acquired by peer QniQure for about $55m.

Allied Minds had invested over $50m in New York University RAM technology spinout Spin Memory, which has decided to liquidate its assets to pay creditors.

Harvard-aligned venture capital firm Xfund has reinvested in ImmuneID, which is developing precision immunology therapies based on Harvard University and Johns Hopkins University research.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

MIT mRNA therapeutics spinout Strand has secured series A funding from BeiGene, Redmile Group, Camford Capital, Playground Global and Anri.

Mission Bay Capital, the venture capital arm of California Institute for Quantitative Biosciences, helped the replacement therapy developer close its series B round.

Impact 12 will deploy equity and debt to finance the development of university social ventures able to deliver a beneficial social or environmental impact.

Boston Scientific has acquired all remaining shares in its portfolio company Farapulse, having first invested in the University of Iowa spinout in 2014.

Theodorus has contributed to a $23.8m series A round for NeuVasQ, the neurological disease drug developer spun out of Université libre de Bruxelles.